Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance - Diacon, A. H.; Donald, P. R.; Pym, A.; Grobusch, M.; Patientia, R. F.; Mahanyele, R.; Bantubani, N.; Narasimooloo, R.; De Marez, T.; van Heeswijk, R.; Lounis, N.; Meyvisch, P.; et al. (Antimicrobial Agents and Chemotherapy, 2012)
Keywords: Acne; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antitubercular Agents; Antitubercular Agents - therapeutic use; Bacterial diseases; Biological and medical sciences; Chest; Clarithromycin - therapeutic use; Clinical Therapeutics; Clinical trials; Cycloserine - therapeutic use; Dapsone - therapeutic use; Diarylquinolines; Drug resistance; Erythromycin - therapeutic use; ethambutol; Ethionamide; Female; Hearing; Human bacterial diseases; Humans; Infectious diseases; Isoxazoles - therapeutic use; Lung; Male; Medical sciences; Mycobacterium; Nausea; Ofloxacin; Ofloxacin - therapeutic use; Oxazolidinones - therapeutic use; Pain; Pharmacokinetics; Pharmacology. Drug treatments; Quinolines - therapeutic use; Sputum; Tuberculosis; Tuberculosis and atypical mycobacterial infections; Tuberculosis, Multidrug-Resistant; Tuberculosis, Multidrug-Resistant - drug therapy; Treatment resistance; Prognosis; Toxicity; Mycobacterial infection; Epidemiology; Long term; Infection; Randomization; Treatment; Tuberculosis; Multiple resistance; Bacteriosis; Clinical trial